The GeneSight Analgesic laboratory developed test analyzes how patients’ genes can affect their metabolism and possible response to FDA-approved opioids, NSAIDs and muscle relaxants commonly used to treat chronic pain. The information from the GeneSight test can help you select the medication(s) and dose(s) that are better suited to your patient’s genetic profile. GeneSight provides an objective and personalized approach to treatment.
The GeneSight pharmacogenomic test was developed in the Assurex Health clinical laboratory and is based on patented technology licensed from two world renowned medical centers, Mayo Clinic and Cincinnati Children’s Hospital Medical Center, who continue to be research collaborators. In clinical use for more than 5 years, GeneSight has over 13,000 registered healthcare providers and over 210,000 patients who have undergone GeneSight testing.
Medications on the GeneSight Panel
The test provides information regarding FDA-approved medications frequently prescribed for chronic pain1
Medications covered by GeneSight Analgesic are FDA-approved for one or more of the following conditions:
Acute and Chronic Pain, Opioid Dependency, Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Juvenile Rheumatoid Arthritis (JRA)
GeneSight Analgesic examines Pharmacokinetic Genes Cytochrome P450 2D6 (CYP2D6), 2C19 (CYP2C19), 2C9 (CYP2C9), 3A4 (CYP3A4), 2B6 (CYP2B6), 1A2 (CYP1A2) and Opioid Pharmacodynamic Gene OPRM1.
Ready to talk to a GeneSight Representative?
1. IMS NDTI quarterly projected drug utilization data from 2014